Summary: Immune checkpoint inhibitors and monoclonal antibodies reinvigorate cancer immunotherapy. However, these immunotherapies only benefit a subset of patients. We previously reported that ALDH high tumor cells were highly enriched for cancer stem cells (CSCs), and ALDH high CSC lysate-pulsed dendritic cell (CSC-DC) vaccine was shown to induce CSC-specific cytotoxic T lymphocytes. In this study, we investigated the CSC targeting effect of the CSC-DC vaccine combined with a dual blockade of programmed death-ligand 1 and cytotoxic Tlymphocyte-associated protein (CTLA-4) in B16-F10 murine melanoma tumor model. Our data showed that animals treated with the dual blockade of programmed death-ligand 1 and CTLA-4 and CSC-DC vaccine conferred significantly more tumor regression than the CSC-DC vaccine alone. Importantly, the triple combination treatment dramatically eliminated ALDH high CSCs in vivo. We observed that CSC-DC vaccine in combination with anti-PD-L1 and anti-CTLA-4 administration resulted in ∼1.7-fold fewer PD-1 + CD8
Summary: Immune checkpoint inhibitors and monoclonal antibodies reinvigorate cancer immunotherapy. However, these immunotherapies only benefit a subset of patients. We previously reported that ALDH high tumor cells were highly enriched for cancer stem cells (CSCs), and ALDH high CSC lysate-pulsed dendritic cell (CSC-DC) vaccine was shown to induce CSC-specific cytotoxic T lymphocytes. In this study, we investigated the CSC targeting effect of the CSC-DC vaccine combined with a dual blockade of programmed death-ligand 1 and cytotoxic Tlymphocyte-associated protein (CTLA-4) in B16-F10 murine melanoma tumor model. Our data showed that animals treated with the dual blockade of programmed death-ligand 1 and CTLA-4 and CSC-DC vaccine conferred significantly more tumor regression than the CSC-DC vaccine alone. Importantly, the triple combination treatment dramatically eliminated ALDH high CSCs in vivo. We observed that CSC-DC vaccine in combination with anti-PD-L1 and anti-CTLA-4 administration resulted in ∼1.7-fold fewer PD-1 + CD8
+ T cells and ∼2.5-fold fewer CTLA-4 + CD8
+ T cells than the populations observed following the CSC-DC vaccination alone. Moreover, significant antitumor effects and dramatically eliminated ALDH high CSCs following the triple combination treatment were accompanied by significantly enhanced T-cell expansion, suppressed transforming growth factor β secretion, enhanced IFN-γ secretion, and significantly enhanced host specific CD8 + T-cell response against CSCs. Collectively, these data showed that administration of a-PD-L1 and a-CTLA-4 combined with CSC-DC vaccine may represent an effective immunotherapeutic strategy for cancer patients in clinical. A particular subpopulation of cancer cells characterized by self-renewing ability and the capacity to initiate, replenish, and expand human tumors, has been reported as cancer stem cells (CSCs). [1] [2] [3] CSCs have been isolated from different human solid tumors including melanoma. 1, 4 The frequency of human melanoma CSCs can reach up to 27%. 4 On the basis of the CSC theory, targeting CSCs should impair tumor growth and decrease the risk of tumor relapse and progression. It has been established that CSCs express several tumor-associated antigens (TAA) that can be recognized by cytotoxic T lymphocytes (CTLs). 5, 6 We previously demonstrated that ALDH high murine squamous carcinoma SCC7 and D5 melanoma cells are highly enriched for CSCs, and the induction of CTLs to CSCs has been observed using ALDH high CSC lysate-pulsed dendritic cell (CSC-DC) vaccination. 7 Recently, accumulating studies have shown that CSC-DC can induce anti-CSC humoral as well as cellular immune responses, resulting in efficient antitumor immunity. [8] [9] [10] [11] These studies have clearly suggested that the potential efficacy of CSC-DC vaccine in targeting CSCs is reliable. However, in general, the effectiveness of cancer vaccines has been less robust than initially expected. 12 A recent meta-analysis showed objective response rates of 8.5% in 1205 advanced melanoma patients treated with DC vaccination. 13 One of the reasons for the lack of efficacy of cancer vaccines is that suppression immune checkpoints (eg, cytotoxic T-lymphocyte-associated protein (CTLA-4), programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and others) inhibit vaccineinduced CTL responses. 14 In the past few years, the successful use of checkpoint inhibitor (CPI) blockade has reinvigorated the field of immunotherapy in cancer. CTLA-4 blockade with ipilimumab represented the first checkpoint inhibition approved by the FDA for the treatment of metastatic melanoma. 15 More recently, applications of the inhibitors of PD-1 and its ligand (PD-L1) by monoclonal antibodies nivolumab and pembrolizumab (anti-PD-1) and atezolizumab (anti-PD-L1) have achieved great success. 16 The prevailing guidelines recommend either anti-PD-1 monotherapy or nivolumab and ipilimumab combination therapy as the standard first-line treatment for unresectable metastatic melanoma based on 2 randomized trials. 17, 18 However, while some patients exhibited partial or even complete responses to CPI therapy, many patients remained unresponsive. 19 The lack of a response in 40%-80% of the patients not benefiting from CPIs are partly related to the characters of tumor-infiltrating lymphocytes (TILs). 20 Obviously, both cancer vaccines and CPIs have shortcomings by themselves. Theoretically, cancer vaccines may generate tumor-specific T cells, which could be enhanced by CPIs that counteract the immune inhibitory mechanisms. To test this hypothesis, we focused on targeting CSCs using the CSC-DC vaccine in this study while simultaneously blocked CTLA-4 and PD-L1 to investigate the effects of the combined cancer immunotherapy utilizing the B16-F10 murine melanoma model.
MATERIALS AND METHODS

Cell Lines and Mice
B16-F10 melanoma cells were obtained from the ATCC (catalog CRL-6475, Shanghai, China) and maintained in RPMI 1640 (Gibco, Invitrogen) containing 10% fetal bovine serum (FBS) (Gibco, Invitrogen), 100 U/ml penicillin and 100 μg/mL streptomycin (Sigma-Aldrich China, Beijing, China). Cells were cultured at 37°C with 95% humidity and 5% CO 2 . The 6-to 8-week-old C57BL/6 (B6) female mice were purchased from Wuhan University Animal Center (Wuhan, China) and maintained under specific pathogen-free conditions in Huazhong University of Science and Technology Animal Facilities. All experiments were approved by the Institutional Animal Care and Use Committee, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and conducted under appropriate supervision.
ALDEFLUOR Assay
It was shown that ALDH was involved in maintaining the subpopulation of cancer stem-like cells in B16-F10 melanoma cells. 21 It has been established that the ALDEFLUOR kit (Stem Cell Technologies, Vancouver, Canada) can be used to isolate stem cells with high ALDH activity in many cancer types. In melanoma, Ning et al 7 and Luo et al 22 reported that the sorted population with high ALDH activity was enriched for melanoma stem cells. The ALDEFLUOR kit (Stem Cell Technologies) was used to isolate CSCs expressing high levels of ALDH from the B16-F10 melanoma cells. For the assay, briefly, cells were suspended in ALDEFLUOR assay buffer containing BODIPY-aminoacetaldehyde and incubated at 37°C for 30 minutes. Control samples were incubated with the buffer containing 50 mM diethylaminobenzaldehyde, an ALDH inhibitor. Cell sorting was conducted using a FACSAria flow cytometer with FACSDiva software (BD Immunocytometry). The ALDEFLUOR staining was detected using the fluorescein isothiocyanat channel. To prevent cross-contamination between ALDH high and ALDH low cells, sorting gates of these 2 populations were set up at least 1 log apart. The purity of sorted populations was reanalyzed using ALDH high and ALDH low cells and was shown to be > 95% ALDH high and ALDH low , respectively.
Preparation of ALDH high CSC Lysate-pulsed DC Vaccination
Tumor cell lysates of ALDH high B16-F10 cells and bone marrow-derived murine DCs were prepared as we previously described. 7 Briefly, tumor cell lysates of unsorted and ALDH high B16-F10 cells were frozen and thawed 3 times to make cell lysate. Bone marrow-derived DCs were cultured in complete medium supplemented with 20 ng/mL IL-4 and 20 ng/mL granulocyte-macrophage colony stimulating factor on day 0. Fresh medium supplemented with 20 ng/mL granulocyte-macrophage colony stimulating factor was added every 2 days. On day 10, DCs were harvested by dispenser and enriched by Opti-Prep density gradient medium.The lysate of ALDH high cells was added to DCs at a 1:3 cell equivalent ratio. The DCs were then incubated at 37°C for 24 hours with 5% CO 2 . After incubation, CSC-DC was used as a vaccine as specified in the subsequent experiments.
Tumor Model B6 mice were inoculated subcutaneously with 0.5 million B16-F10 cells on day 0. The animals were divided into 6 groups (n = 5). One group of mice was administered with PBS; 1 group of mice was administered with unsorted tumor cell lysate-pulsed DC vaccine (H-DC), and 4 groups of mice were administered with CSC-DC vaccine 3 days after B16-F10 cell inoculation. The vaccination was repeated on days 6 and 9. Each mouse was inoculated subcutaneously with 1 million DCs per vaccine. In the CSC-DC vaccination groups, 100 μg anti-CTLA-4 (clone 9D9; Bio X Cell, West Lebanon, NH) and/or anti-PD-L1 (clone10F.9G2; Bio X Cell, West Lebanon, NH) or control rat immunoglobulin (IgG) were administered intraperitoneally, on days 3, 6, and 9 following the B16-F10 cell inoculation. Tumor size was recorded 3 times per week by measuring the width and length diameters of the tumors.
Immunophenotyping of the Splenocytes
Spleens were harvested from the treated animals. Splenocytes were prepared by mashing the spleens with 70-μm strainers. Red blood cells were lysed with red blood cell lysis buffer. CD3 + T cells were sorted by fluorescence-activated cell sorting (FACS). To identify the immunophenotypies of the T splenocytes, sorted CD3 + T cells were directly stained with antibodies for phenotype characterization by flow cytometry. PEconjugated anti-CTLA-4 and phycoerythroprotein-conjugated anti-PD-1 were used in conjunction with fluorescein isothiocyanat-conjugated anti-CD8. All antibodies were obtained from eBioscience (San Diego, CA).
T-Cell Activation
CD3
+ T splenocytes harvested from the treated animals were activated by anti-CD3/anti-CD28 followed by IL-2 expansion as we previously described. 7, 11 T-cell proliferation was detected by a WST-8 Cell Counting Kit-8 (Beyotime C0037, Wuhan, China) according to the manufacturer's protocol. Briefly, a 100 μL activated T-cell suspension from each group was transferred into a 96-well plate. Next, 20 μL CCK-8 solution was added to each well for a 2-hour incubation period at 37°C. The absorbance was then measured using a microplate reader (Bio-Rad, CA) at 450 nm with a reference wavelength of 650 nm. Each sample was performed in triplicate.
Cytokine Production
Cytokines produced by activated/expended splenic T cells into the supernatants of cell culture were detected by ELISA. Commercially available ELISA kits specific for mouse interferon (IFN-γ), transforming growth factor β (TGF-β), and interleukin 10 (IL-10) (all from R&D Systems, MN) were used as indicated by the manufacturer's protocols.
CTL Cytotoxicity
CTLs were generated from the splenocytes harvested from the treated animals by anti-CD3/anti-CD28 activation and IL-2 expansion as previously described. CTLmediated CSC cytotoxicity was tested using the lactate dehydrogenase (LDH) release assay (CytoTox 96 NonRadioactive Cytotoxicity Assay; Promega, Madison, WI) according to the manufacturer's protocol. Briefly, the control and experimental wells were set up in a round 96-well culture plate. In the experimental wells, effector cells (CTLs) and target cells (ALDH high B16-F10 cells) with different ratios were incubated at 37°C for 4 hours. Then, LDH measurements were performed according to the protocol. The reality of cytotoxicity was calculated as follows:
% Cytotoxicity¼
ExperimentalÀEffector SpontaneousÀTarget Spontaneous Target MaximumÀTarget Spontaneous Â100:
Statistical Analyses
Statistical analyses were performed using GraphPad Prism 5.0 software (GraphPad Software Inc., San Diego, CA). Data were evaluated by unpaired Student t test or 1-way analysis of variance. The statistical significance was set at P < 0.05.
RESULTS
CSC-DC Vaccination Combined With Immune Checkpoint Blockades Promoted Tumor Eradication
We previously demonstrated that CSC-DC vaccines could induce more effective antitumor immunity than H-DCs. 7 In this setting, we tested whether simultaneous blockade of PD-L1 and/or CTLA-4 with CSC-DC vaccine could induce stronger antitumor immunity than CSC-DC vaccine alone. As shown in Figure 1 , compared with phosphate buffer saline (PBS) and H-DC-treated mice, CSC-DC vaccination significantly inhibited tumor growth, which corroborated our previous observations. 7 Although we failed to observe the combination of either anti-PD-L1 or anti-CTLA-4 with CSC-DC vaccinations to induce more significant tumor regression than CSC-DC vaccination alone, we did find that the triple combination (CSC-DC vaccination/anti-PD-L1/anti-CTLA-4) treatment induced far more significant tumor regression than CSC-DC vaccination alone (P = 0.038). These experiments clearly indicated that simultaneous PD-L1 and CTLA-4 blockades could significantly boost the antitumor immune response induced by CSC-DC vaccination in the B16-F10 melanoma model.
CSC-DC Vaccination Combined With Immune Checkpoint Blockades Enhanced the Elimination of ALDH high CSCs In Vivo
To confirm that CSCs were effectively targeted by CSC-DC vaccination combined with PD-L1/CTLA-4 blockades, we determined the number of ALDH high CSCs in the residual tumors after treatments. The results are shown in Figure 2 . The CSC-DC vaccination-treated mice contained (5.8% ± 0.4%) ALDH high cells, which was significantly less than the number in the H-DC-treated mice (9.3% ± 0.5%) and the PBS-treated mice (11.2% ± 0.7%). The combination treatment of CSC-DC vaccinations with anti-PD-L1 or anti-CTLA-4 or the triple combination treatment significantly reduced the number of ALDH high cells in the residual tumor of the treated mice to 3.9% ± 0.2%, 4.4% ± 0.6%, and 2.1% ± 0.6%, respectively. Of note, the dual blockade of PD-L1 and CTLA-4 combined with CSC-DC vaccinations dramatically eliminated the ALDH high cells in vivo compared with CSC-DC (P = 0.0058) or CSC-DC combined with anti-PD-L1 (P = 0.0038) or CSC-DC combined with anti-CTLA-4 (P = 0.0027), respectively.
CSC-DC Vaccination Combined With Immune Checkpoints Blockade Enhanced the Proliferation of Functional CD8 + T Cells
To understand the effects of the CSC-DC vaccine combined with anti-PD-L1/anti-CTLA-4 in vivo, we analyzed the immunologic characteristics of T cells from spleens in each treated group of mice at the end of the experiment (day 30). CSC-DC vaccination induced a preferential expansion of CD8 + T cells (∼35% of the splenocytes), which was higher than that of the PBS group and the H-DC vaccination group (P < 0.05). Importantly, while the CD8 + T cells of mice treated with the CSC-DC vaccine in combination with anti-PD-L1 or anti-CTLA-4, respectively, showed a similar percentage of CD8 + T cells in the spleen of mice as those vaccinated with CSC-DC alone (Fig. 3A) , the CD8 + T cells of mice treated with the CSC-DC vaccine in combination with both anti-PD-L1 and anti-CTLA-4 revealed a significant (P = 0.034) higher percentage of CD8 + T cells than those in the spleen of mice vaccinated with CSC-DC alone.
A number of studies have indicated that melanoma induces T-cell exhaustion in the tumor microenvironment (TME). 23, 24 It is now well established that higher and sustained expression of inhibitory receptors (such as CTLA-4, PD-1) is a hallmark of exhausted T cells. 25 To determine the exhausted T cells in the CSC-DC vaccine treatment, CTLA-4 + CD8 + T cell and PD-1 + CD8 + T-cell populations were evaluated in the spleens of each treated group of mice as indicated. This analysis revealed that compared with the populations observed in the H-DC vaccination group, CSC-DC vaccination induced ∼1.2-fold (8.18% vs. 6.75%) more PD-1 + CD8 + T cells (Figs. 3B, D) and ∼1.5-fold (10.50% vs. 7.00%) more CTLA-4 + CD8 + T cells (Figs. 3C, E) . It was interesting to note that CSC-DC vaccination combined with anti-PD-L1 or anti-CTLA-4, respectively, resulted in lower PD-1 + CD8 + T cells (P = 0.047) and CTLA-4 + CD8 + T cells (P = 0.043) than CSC-DC vaccination alone. More importantly, triple combination treatment resulted in ∼2.5-fold (4.27% vs. 10.50%) significantly (P = 0.018) fewer CTLA-4 + CD8 + T cells than the populations observed in CSC-DC vaccination alone (Figs. 3C, E) . Similarly, the triple FIGURE 1. Inhibition of tumor growth by CSC-DC vaccination combined with immune checkpoints blockade. B6 mice were inoculated subcutaneously with 0.5 million B16-F10 cells on day 0 and treated with H-DC or CSC-DC vaccine on day 3. The vaccination was repeated on days 6 and 9. Anti-CTLA-4, anti-PD-L1, or control immunoglobulin (IgG) were administered intraperitoneally in some of the groups as indicated on days 3, 6, and 9 following tumor inoculation. Tumor size in each group of mice treated as indicated (n = 5). CSC-DC vaccination, ALDH high CSC lysate-pulsed DC vaccination. CSC indicates cancer stem cell; DC, dendritic cell; H-DC vaccination, unsorted tumor cell lysate-pulsed dendritic cell vaccination. combination treatment resulted in ∼1.7-fold (4.60% vs. 8.18%) significantly (P = 0.004) fewer PD-1 + CD8 + T cells than the populations observed in CSC-DC vaccination alone (Figs. 3B, D) .
We also performed T-cell proliferation assay in vitro. The T-cell proliferation was then analyzed by a WST-8 Cell Counting Kit-8. In this assay, the triple combination treatment induced a significant (P = 0.023) increase in the proliferation of T cells compared with the proliferation observed in CSC-DC vaccine alone group (Fig. 4A) , even though CSC-DC vaccination combined with anti-PD-L1 or anti-CTLA-4, respectively, resulted in a minimum increase in T-cell proliferation compared with CSC-DC vaccination alone.
The immune activity of the T-cell proliferation was characterized by measuring IFN-γ, TGF-β, and IL-10 cytokines produced by these activated and expended splenic T cells into the culture supernatants. As showed in Figure 4B , TGF-β secretion was suppressed following CSC-DC vaccination and was further suppressed after the triple combination treatment (P = 0.028). Furthermore, IL-10 secretion was also decreased following CSC-DC vaccination and remained decreased after the combination treatments. In contrast, IFN-γ secretion was significantly augmented following CSC-DC vaccination and was further elevated after the triple combination treatment (P = 0.031). Together, these data suggested that the immune checkpoints PD-L1 and CTLA-4 blockades may reverse the exhausted T cells induced by CSC-DC vaccine.
CSC-DC Vaccination Combined With Immune Checkpoints Blockade Enhanced Host CSCspecific CTL Activity
We further examined the ability of CSC-DC vaccination combined with anti-PD-L1/anti-CTLA-4 to induce CSC-specific CTL activity in vitro. Cytotoxic T cells from spleens of treated mice were generated as previously described. Target cells were sorted B16-F10 ALDH high cells. As in Figure 5 , CTLs from the triple combination treatment group mediated significantly greater cytotoxicity against the B16-F10 ALDH high cells at high E:T ratios (3:1 and 10:1) compared with the CTLs generated from PBS, H-DC, CSC-DC, and CSC-DC combined with anti-PD-L1 or anti-CTLA-4 (P < 0.05). We previously demonstrated that CSC-DC vaccine induced more effective antitumor immunity than H-DC. 7 In the present study, we observed that CTLs generated from mice subjected to CSC-DC vaccination induced stronger cytotoxicity than CTLs generated from the H-DC vaccination group, which corroborated our previous observation. 7 Although CTLs generated from the splenocytes of mice subjected to CSC-DC vaccination combined with anti-PD-L1 or anti-CTLA-4, respectively, failed to enhance the cytotoxicity compared with CTLs generated from the CSC-DC vaccination alone group (Fig. 5) , CSC-DC vaccination plus PD-L1 as well as CTLA-4 blockades triple combination treatment conferred significantly stronger host CTL responses against ALDH high CSCs than the CSC-DC vaccination alone or its combination with a single immune checkpoint, for example, PD-L1 or CTLA-4 blockade.
DISCUSSION
Various melanoma vaccines have been explored. 26, 27 However, limited success has been achieved, particularly in the metastatic setting. With further understanding of the melanoma TME, it is becoming clear that immune checkpoints play an important role in T-cell exhaustion in TME. For example, CTLA-4 engagement suppresses T-cell activation by blocking T-cell costimulation, whereas binding of PD-1 with its ligands PD-L1 and PD-L2 inhibits T-cell activity by promoting anergy, death, or exhaustion in tumor. 28, 29 The recent successes of CPIs, for example, anti-CTLA-4 and anti-PD-1 are promising. However, a significant number of the patients are not benefiting from CPIs, which makes it necessary to pursue treatment together with other strategies, such as a combination of cancer vaccines with CPIs. 20 Targeting CSCs may impair tumor growth and decrease the risk of tumor relapse and progression. 1, 30 We focused on CSCs as a target of cancer immunotherapy to achieve more efficient antitumor responses. In this study, we illustrated that blockade of both PD-L1 and CTLA-4 pathways significantly enhanced CSC-DC vaccine-induced host immune responses against CSCs in vivo. Elucidating the mechanism underlying these effects indicated that such combination therapy enhanced the CD8 + T-cell population and reversed T-cell exhaustion, ultimately enhancing host CSC-specific CTL activity.
Several studies have shown successful use of cancer vaccines in combination with 2 CPIs (α-CTLA-4 and α-PD-L1/α-PD-1). [31] [32] [33] [34] [35] However, our study provides the first evidence that cancer vaccines in combination with CPIs could reduce the number of CSCs due to the use of a CSC-targeted vaccine in melanoma. In our previously study, we demonstrated that ALDH high tumor cells were highly enriched in CSCs, and ALDH high CSC-DC vaccines could induce more effective antitumor immunity than DCs pulsed with the lysate of unsorted tumor cells (H-DC) or sorted ALDH low cells. In addition, we showed in several reports that CSC-DC vaccine-conferred antitumor immunity was associated with CSC-DC vaccine-induced anti-ALDH high CSCs versus ALDH low non-CSCs. 7, 8, 11 The present study showed that α-PD-L1 or α-CTLA-4 alone failed to enhance the antitumor effects of the CSC-DC vaccines in melanoma. In contrast, we reported that murine squamous carcinoma SCC7 CSC-DC vaccine limited local tumor recurrence and spontaneous pulmonary metastasis, with increased host survival, which was further accentuated by simultaneous PD-L1 blockade. 11 These studies suggested that the efficacy of cancer vaccine in combination with CPIs is tumor model-dependent, and is also dependent on the dosages of the CPIs tested.
Curran and colleagues demonstrated that the combination of αCTLA-4 and αPD-1 is more than twice as effective in promoting the rejection of B16 melanoma as either alone or in conjunction with Fvax vaccines, and that addition of αPD-L1 elevated the rate of tumor-free survival from this triple combination treatment. 34 In contrast, the duration time after tumor inoculation may affect the observation of antitumor effects. Our results indicated that the longer after tumor inoculation, the stronger the antitumor effects were observed. The observation time of our study was 30 days after tumor inoculation, and the survival rate was not observed, which was a limitation of this study.
It has been established that T cells are exhausted after long-term exposure to the tumor antigens in melanoma. 36 The B7/CTLA-4 and PD-1/PD-L1 pathways mediate T-cell exhaustion by antagonizing activation signaling pathways. 25 Furthermore, the PD-1 and CTLA-4 pathways operate at different stages of the immune responses. 37 Spurred by the impressive effects of the combination of CTLA-4 and PD-1 blockade in melanoma, 38 a large number of immunotherapy combinations, such as combining different CPIs or CPIs with a therapeutic cancer vaccine, are now being clinically evaluated. We combined α-CTLA-4 and α-PD-L1 due to the following considerations: first, the CTLA-4 blockade induces a proliferative signature predominantly in a subset of transitional memory T cells, 39 while the PD-L1 blockade decreases the number and/or the suppressive activity of regulatory T cells and rescues the activity of effector T cells. 40 Second, the PD-L1 blockade decreases the percentages of the highly immunosuppressive myeloid-derived suppressor cells. 41 Third, PD-L1 mRNA and protein can be upregulated by cytokines produced by TILs, such as IFN-γ. 42 Fourth, melanoma-PD-1:PD-L1 interactions promote tumor growth, 43 and PD-L1 expression is an independent, poor prognostic factor for malignant melanoma. 44 In this study, combined α-CTLA-4/α-PD-L1 and CSC-DC vaccine have shown synergistic antitumor effects by targeting CSCs.
Elucidating the mechanism underlying the antitumor effects in the present study indicated that combined α-CTLA-4/α-PD-L1 and CSC-DC vaccine enhanced the number of circulating functional CD8 + T cells. Studies have shown that exhausted T cells upregulate inhibitory receptors, including PD-1 and CTLA-4. 23 We investigated whether our treatment had the ability to restore the exhausted T cells. We checked the phenotype profiles of T cells from the splenocytes. The data showed that the expressions of PD-1 and CTLA-4 on CD8 + T cells were dramatically downregulated in mice treated with the triple combination therapy. Additional data showed that the triple combination therapy induced the robust expansion of CD3 + T cells and enhanced the production of several immunoinhibitory cytokines, such as IFN-γ. We also found that combined α-CTLA-4/α-PD-L1 and CSC-DC vaccineinduced CTLs significantly killed the ALDH high CSCs compared with the CTLs induced by H-DC, or by CSC-DC combined with either α-CTLA-4 or α-PD-L1 alone. These results indicate that this triple combination therapy confers strong CTL activity that specifically target CSCs. In addition, exhausted T cells are characterized by a progressive loss of their functional capacities to proliferate, produce cytokines, and lyse upon chronic antigen exposure. 25 From this point of view, this triple combination therapy reversed T-cell functions, which provides certain novel insights into the mechanisms of this combination therapy. The limitation of elucidating the mechanism underlying this combination therapy in the present study was that we did not illuminate the affection of the absolute number of CD8 + T cells. It will take a lot of time and effort to illuminate this issue. However, in our next experiment, we plant to quantify the TIL density both in the tumor parenchyma and at the invasive tumor margin at the endpoint.
In conclusion, our work suggests that administration of a-PD-L1 and a-CTLA-4 with CSC-DC vaccine could reverse T-cell functions and induce more effective T-cell activation, proliferation, as well as the function of CTLs targeting CSCs. Our study provides the scientific basis for a clinical trial that would involve the combination of CSC-DC vaccine and simultaneous PD-L1 and CTLA-4 blockades for sustained tumor control in patients with cancer.
